Quick Answer
Crinetics Pharmaceuticals, Inc. reported Operating Income Loss of -$516.77 million for the year ending 2025.
- Crinetics Pharmaceuticals, Inc. showed a decrease of -52.5% in Operating Income Loss from 2024 to 2025.
- This data is from Crinetics Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Crinetics Pharmaceuticals, Inc.'s Operating Income Loss has declined by 8,450.1%.
- Historical annual values: Fiscal year 2025: -$516.77 million | Fiscal year 2024: -$338.85 million | Fiscal year 2023: -$222.61 million | Fiscal year 2022: -$167.88 million | Fiscal year 2021: -$107.70 million | Fiscal year 2020: -$74.95 million | Fiscal year 2019: -$53.83 million | Fiscal year 2018: -$28.71 million | Fiscal year 2017: -$9.13 million | Fiscal year 2016: -$6.04 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: